Metaxalone News
King Pharmaceuticals Reports FDA Approval of New Skelaxin(R) Label
King Pharmaceuticals (NYSE: KG) reported today that the U.S. Food and Drug Administration ("FDA") has approved the Company's revised prescribing information for its Skelaxin(R) (metaxalone) product. Skelaxin(R) is a leading...
Eon labs says generic muscle drug to be delayed
Eon Labs Inc. said its generic version of the Elan Corporation's Skelaxin muscle relaxant would be delayed after regulators rejected a study of the drug.
King Pharmaceuticals Reports First-Quarter 2006 Financial Results
King Pharmaceuticals, Inc. KG announced today that total revenues increased 31% to $484 million during the first quarter ended March 31, 2006, compared to $369 million in the first quarter of 2005.
Elan raises €55m in new sell-off
Irish pharmaceutical group Elan has raised around $70 million (€55m) from four new deals, including the sale of formulation and manufacturing interests.
King Pharmaceuticals posted a monthly rise of 31%, sparked by favorable second-quarter results
The generic-drug maker posted earnings of 44 cents per share, exceeding the Street estimate by 24 cents. The key drivers during the quarter were Altace, Skelaxin and Sonata. Standard & Poor's Equity Research raised the target...